Wright Clinical Research LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$1,377	1
2023	Research	$11,740	25
2022	Research	$33,316	13
2021	Research	$113,044	31
2020	Research	$157,895	76
2019	Research	$15,437	6

Breakdown

Who paid Research payments · program years 2019–2024

Takeda Pharmaceuticals U.S.A., Inc. $185,221 77 payments
Jazz Pharmaceuticals Inc. $63,772 51 payments
GlaxoSmithKline, LLC. $39,602 7 payments
AbbVie, Inc. $24,154 11 payments
AstraZeneca Pharmaceuticals LP $20,062 6 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 1B Randomized, Double-Blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of Tak-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of Cpap $84,203 12 payments
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) $51,585 15 payments
A Phase 4 Multicenter, Open-Label, Single-Arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $31,851 33 payments
A Phase 1B Randomized, Double-Blind, Placebo-Controlled, Crossover Study of A Single Intravenous Infusion Dose of Tak-925 in Patients With Idiopathic Hypersomnia $28,595 44 payments
M16-100 $21,437 5 payments
A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension $20,349 14 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $16,770 2 payments
A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $15,420 2 payments
A Phase 4 Multicenter Open-Label Single-Arm Study of Safety Tolerability Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $11,572 4 payments
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) $11,237 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.